<SEC-DOCUMENT>0001193125-22-125649.txt : 20220428
<SEC-HEADER>0001193125-22-125649.hdr.sgml : 20220428
<ACCEPTANCE-DATETIME>20220428092656
ACCESSION NUMBER:		0001193125-22-125649
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220428
FILED AS OF DATE:		20220428
DATE AS OF CHANGE:		20220428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			I-Mab
		CENTRAL INDEX KEY:			0001778016
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39173
		FILM NUMBER:		22862594

	BUSINESS ADDRESS:	
		STREET 1:		55TH-56TH FLOOR, NEW BUND CENTER
		STREET 2:		555 WEST HAIYANG ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			200124
		BUSINESS PHONE:		862160578000

	MAIL ADDRESS:	
		STREET 1:		55TH-56TH FLOOR, NEW BUND CENTER
		STREET 2:		555 WEST HAIYANG ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			200124
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d335653d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of April 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-39173</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>55th &#150;
56th Floor, New Bund Center, 555 West Haiyang Road, Pudong District </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Shanghai, 200124 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>People&#146;s Republic of China </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F</FONT> &nbsp;&nbsp;&#9746;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form <FONT STYLE="white-space:nowrap">40-F</FONT> &nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="white-space:nowrap">I-MAB</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By :</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Long</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">John Long</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title :</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director and Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: April&nbsp;28, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d335653dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g335653g0428012446199.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Announces Appointments of Richard Yeh as Chief Operating
Officer and John Hayslip as Chief Medical Officer </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Biotech and Wall Street veteran Mr.</I><I></I><I>&nbsp;Richard Yeh to focus on strategic investor
interactions, global alliance management and facilities as COO</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Renowned oncology expert Dr.</I><I></I><I>&nbsp;John Hayslip to further accelerate global clinical development
of <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> innovative pipeline as CMO</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SHANGHAI, China and GAITHERSBURG,
MD.</B><B></B><B>&nbsp;April 28, 2022</B><B></B>&nbsp;&#150; <FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">(&#147;I-Mab&#148;</FONT> or the &#147;Company&#148;) (Nasdaq: IMAB), a clinical-stage biopharmaceutical
company committed to the discovery, development, and commercialization of novel biologics,&nbsp;announced today the appointments of Mr.&nbsp;Richard Yeh as Chief Operating Officer and Dr.&nbsp;John&nbsp;Hayslip&nbsp;as Chief Medical Officer. The two
key appointments add greater depth and breadth of industry experience to the Company&#146;s leading management team, further accelerating its global ambition in innovation and to become a specialty global biopharmaceutical company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">&#147;I-Mab</FONT> has been on an exciting transformation journey. As we continue to push forward on multiple fronts to
expand our capabilities and deliver on key milestones, the invaluable experience brought by these two leaders will facilitate the Company&#146;s growth to the next phase,&#148; said Dr.&nbsp;Jingwu Zang, Founder, Chairman and Acting CEO of <FONT
STYLE="white-space:nowrap">I-Mab.</FONT> &#147;Mr.&nbsp;Yeh will play an integral role in further enhancing our global investor network and strengthening our global business partnerships. While Dr.&nbsp;Hayslip&nbsp;will apply his nearly two decades
of clinical research expertise in&nbsp;oncology&nbsp;to advancing our globally competitive pipeline of innovative assets.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Yeh will be
based in Shanghai,&nbsp;China&nbsp;and report directly to Dr.&nbsp;Jingwu Zang. He will join <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> Board after the necessary process is completed. As the Company upgrades its worldwide operations and
strengthens network with international investors, Mr.&nbsp;Yeh will be leading key aspects of <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> strategic investor interactions, global alliance management and major facilities across the world.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Yeh is an industry veteran with over 25 years of experience spanning senior leadership positions with biopharmaceutical companies and prominent
Wall Street firms. Before joining <FONT STYLE="white-space:nowrap">I-Mab,</FONT> Mr.&nbsp;Yeh was&nbsp;Chief Financial Officer and Head of Strategic Operations at&nbsp;Abbisko&nbsp;Therapeutics&nbsp;(HKEX: 2256), overseeing financial transactions,
strategic planning, financial&nbsp;&amp; accounting reports, risk management and fundraising. He also held a series of leadership positions including Chief Financial Officer of CStone Pharmaceuticals (HKEX: 2616), Managing Director and Business Unit
Leader of Asia Pacific healthcare equity research at Goldman Sachs (Asia), and Head of China and regional healthcare research team at Citigroup Capital Markets Asia. Mr.&nbsp;Yeh also had robust experience in equity research covering the U.S.
biotechnology sector at major firms including Citigroup and Bank of America Securities. Before his career on Wall Street, Mr.&nbsp;Yeh worked in the global strategic marketing group at Wyeth Pharmaceuticals and conducted drug discovery research at
Amgen. Mr.&nbsp;Yeh earned his M.B.A. from the Samuel Curtis Johnson Graduate School of Management at Cornell University and Master of Science in Medical Biophysics from the University of Toronto and Ontario Cancer Institute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am thrilled to join <FONT STYLE="white-space:nowrap">I-Mab,&#148;</FONT> said Mr.&nbsp;Yeh. <FONT STYLE="white-space:nowrap">&#147;I-Mab</FONT> has
been at the forefront of creating globally competitive innovation and developed an extensive network of strategic partnerships with major players around the world. I am excited to be part of <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT>
global ambition by working with such a high-caliber management team.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shanghai (HQ)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suites 802, 505, 702, West
Tower</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">88 Shangke Road, Pudong New District Shanghai, China</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 710, 9801 Washingtonian
Blvd Gaithersburg</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Maryland 20878</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U><FONT STYLE="white-space:nowrap">www.i-mabbiopharma.com</FONT></U></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g335653g0428012446199.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Hayslip&nbsp;will be based in the United&nbsp;States&nbsp;and report directly to Dr.&nbsp;Andrew
Zhu, President of <FONT STYLE="white-space:nowrap">I-Mab.</FONT> In his new role, Dr.&nbsp;Hayslip&nbsp;will lead the Company&#146;s pipeline development, addressing the key challenges in clinical sciences to increase the probability of success and
the speed of clinical development for <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> innovative assets.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before joining <FONT
STYLE="white-space:nowrap">I-Mab,</FONT> Dr.&nbsp;Hayslip&nbsp;was Vice President of Clinical Development at&nbsp;Nektar&nbsp;Therapeutics (Nasdaq: NKTR). Dr.&nbsp;Hayslip also led development activities for multiple therapies while at AbbVie
Oncology. He also comes with a depth of experience on&nbsp;lemzoparlimab (TJC4), having assembled and led the AbbVie cross-functional team to complete setup for patient enrollment for the global partnership between
<FONT STYLE="white-space:nowrap">I-Mab</FONT> and AbbVie on&nbsp;lemzoparlimab.&nbsp;Prior to joining AbbVie Oncology, Dr.&nbsp;Hayslip&nbsp;was an accomplished researcher and physician at the University of Kentucky&#146;s Markey Cancer Center,
where he led numerous cancer research studies with a primary focus in lymphoma and leukemia. He also served as the Chief for Hematology and Bone Marrow Transplant and as Director of Clinical Research and Data Management at the Markey Cancer Center.
Dr.&nbsp;Hayslip&nbsp;received his medical degree from Northeast Ohio Medical University and a master&#146;s degree in Clinical Research from the Medical University of South Carolina. Following his residency in internal medicine,
Dr.&nbsp;Hayslip&nbsp;completed his fellowship in Hematology-Oncology at the Medical University of South Carolina leading to dual board&nbsp;certifications&nbsp;in both Hematology and Medical Oncology. Dr.&nbsp;Hayslip&nbsp;holds multiple U.S. and
international patents and has published dozens of scientific papers and reviews in renowned journals including<I>&nbsp;Lancet</I><I></I><I>&nbsp;Haematology, Clinical Cancer Research, Leukemia Research, Blood, and Journal of Clinical Oncology</I>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">&#147;I-Mab&#146;s</FONT> focus on transformational therapies to address unmet medical needs through innovation has been
an inspiration,&#148; said Dr.&nbsp;Hayslip. &#147;I am excited to work with this talented global team and looking forward to bringing innovative cancer therapies to patients in areas of high unmet need.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
<FONT STYLE="white-space:nowrap">I-Mab</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> (Nasdaq: IMAB) is an innovation-driven global biopharma
company focused on the discovery, development and commercialization of novel and highly differentiated biologics for immuno-oncology diseases. The Company&#146;s mission is to bring transformational medicines to patients around the world through
innovation. <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> globally competitive pipeline of more than 20 clinical and preclinical-stage drug candidates is driven by its internal discovery and global partnerships for <FONT
STYLE="white-space:nowrap">in-licensing,</FONT> based on the Company&#146;s
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Proof-of-Concept</FONT></FONT></FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> development strategies. The Company is progressing from a clinical-stage biotech company into an innovative global specialty biopharmaceutical company with cutting-edge R&amp;D capabilities, a
world-class GMP manufacturing facility, and commercial capability. <FONT STYLE="white-space:nowrap">I-Mab</FONT> has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and
Maryland and San Diego in the United States. For more information, please visit <U><FONT STYLE="white-space:nowrap">http://www.i-mabbiopharma.com</FONT></U> and follow <FONT STYLE="white-space:nowrap">I-Mab</FONT> on <U>LinkedIn</U>, <U>Twitter</U>,
and <U>WeChat</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shanghai (HQ)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suites 802, 505, 702, West
Tower</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">88 Shangke Road, Pudong New District Shanghai, China</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 710, 9801 Washingtonian
Blvd Gaithersburg</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Maryland 20878</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U><FONT STYLE="white-space:nowrap">www.i-mabbiopharma.com</FONT></U></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g335653g0428012446199.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities
laws, including the statements regarding the Company&#146;s future dual listing plan, its plan to comply with applicable laws and regulations and its strategic goals in the future. Actual results may differ materially from those indicated in the
forward-looking statements as a result of various important factors, including but not limited to <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> compliance with all applicable laws and regulations, further developments of the regulatory
landscape that <FONT STYLE="white-space:nowrap">I-Mab</FONT> is subject to, as well as those risks are more fully discussed in the &#147;Risk Factors&#148; section in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> most recent annual report on
Form <FONT STYLE="white-space:nowrap">20-F,</FONT> and the discussions of potential risks, uncertainties, and other important factors in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> subsequent filings with the SEC. All forward-looking
statements are based on information currently available to <FONT STYLE="white-space:nowrap">I-Mab,</FONT> and <FONT STYLE="white-space:nowrap">I-Mab</FONT> undertakes no obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise, except as may be required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Contacts
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">John Long</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">IR@i-mabbiopharma.com</FONT></U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gigi Feng <BR>Chief Communications Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U><FONT
STYLE="white-space:nowrap">PR@i-mabbiopharma.com</FONT></U></P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Inquiries </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>The Piacente Group, Inc.</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Emilie Wu</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> <U>emilie@thepiacentegroup.com</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Office line: +86 21 6039 8363</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shanghai (HQ)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suites 802, 505, 702, West
Tower</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">88 Shangke Road, Pudong New District Shanghai, China</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 710, 9801 Washingtonian
Blvd Gaithersburg</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Maryland 20878</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><U><FONT STYLE="white-space:nowrap">www.i-mabbiopharma.com</FONT></U></TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g335653g0428012446199.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g335653g0428012446199.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Y )P# 2(  A$! Q$!_\0
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M8OA*'_A'[FT>WM6O93(5F*="S$CG&>]%X"M,M:CJ,=EI-G+!I\4LTX7R[?
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@KK-A:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:2BB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
